This study is an open-label, single-arm, prospective, exploratory clinical trial involving patients with relapsed/refractory large B-cell lymphoma, aiming to preliminarily assess the safety and efficacy of CAR-T cell infusion.
1. The participant has given consent and signed the informed consent form, and is willing and able to comply with planned visits, research treatments, laboratory tests, and other trial procedures;
Anti-CD20 monoclonal antibody;
Combination chemotherapy containing anthracyclines.
3. Age 18 years and above, both male and female;
1. Severe heart failure with left ventricular ejection fraction <50%;
2. History of severe pulmonary dysfunction;
3. Concurrent progressive malignant tumors;
4. Severe infections that cannot be effectively controlled;